Verve Therapeutics, Inc.·4

Sep 19, 5:05 PM ET

Fiedorek Fred T. 4

4 · Verve Therapeutics, Inc. · Filed Sep 19, 2023

Insider Transaction Report

Form 4
Period: 2023-09-18
Fiedorek Fred T.
Chief Medical Officer
Transactions
  • Award

    Stock Option (right to buy)

    2023-09-18+180,000180,000 total
    Exercise: $12.71Exp: 2033-09-17Common Stock (180,000 underlying)
Footnotes (1)
  • [F1]The option was granted on September 18, 2023. 25% of the shares underlying the option will vest on September 18, 2024, and the remainder are scheduled to vest in equal monthly installments thereafter until September 18, 2027.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION